Gamida Cell reports Q2 EPS (31c), consensus (19c)

Reports as of June 30 Gamida Cell had total cash and cash equivalents of $54.1M compared to $64.7M as of December 31, 2022. The decrease of $10.4 million is due primarily to net cash used in operating activities of $44.3M partially offset by $34.7 M net cash proceeds from the issuance of shares and .”Since the approval of Omisirge in April, Gamida Cell has made excellent progress on the launch,” said Abbey Jenkins, President and Chief Executive Officer of Gamida Cell. “We have rapidly confirmed significant payer coverage and are seeing high interest from transplant centers, exceeding our plans. This is a testament to the unmet needs that Omisirge has the potential to address for patients, as well as the exceptional work of our experienced cell therapy team. We continue to progress our discussions in our efforts to secure a strategic deal to fully resource our Omisirge commercial efforts. We are optimistic that between our progress on the Omisirge launch and our discussions with potential partners, we can accelerate efforts to expand patient access to Omisirge.”